(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/062556 A8

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 31/20* (2006.01)

(21) International Application Number:
PCT/IB2022/059774

(22) International Filing Date:
12 October 2022 (12.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/256,283	15 October 2021 (15.10.2021)	US
63/293,220	23 December 2021 (23.12.2021)	US
63/373,539	25 August 2022 (25.08.2022)	US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, NY 10001-2192 (US).

(72) Inventors: **BENNETT, Eric Matthew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **DIAZ, Fernando Martin**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **DORMITZER, Philip Ralph**; 73 Old Orchard Road, Sherborn, Massachusetts 01770 (US). **JANSEN, Kathrin Ute**; 200 E 66th Street, Apt. 11C, New York, New York 10065 (US). **MUNOZ-MORENO, Raquel**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SOLORZANO QUIJANO, Alicia**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(48) Date of publication of this corrected version:
17 August 2023 (17.08.2023)

(15) Information about Correction:
see Notice of 17 August 2023 (17.08.2023)

(54) Title: RNA MOLECULES

(57) Abstract: The present disclosure relates to RNA molecules encoding a varicella zoster virus (VZV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment or prevention of herpes zoster or shingles.

WO 2023/062556 A8